Atossa Therapeutics首席执行官将在第27届H.C. Wainwright全球投资大会上讨论临床进展和即将到来的里程碑-动脉网

Atossa Therapeutics CEO to Discuss Clinical Progress and Upcoming Milestones at 27th Annual H.C. Wainwright Global Investment Conference

CISION 等信源发布 2025-08-28 20:30



可切换为仅中文







Dr.

博士

Steven Quay

史蒂文·奎伊

, Chairman and Chief Executive Officer to participate in Fireside Chat with

董事长兼首席执行官将参与炉边谈话

Emily Bodnar

艾米丽·博德纳尔

, HCW Biotech Research Analyst

，HCW生物技术研究分析师

SEATTLE

西雅图

，

Aug. 28, 2025

2025年8月28日

/PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq:

/PRNewswire/ -- Atossa Therapeutics, Inc.（纳斯达克：

ATOS

阿托斯

) ('Atossa' or the 'Company'), a clinical-stage biopharmaceutical company developing new approaches in breast cancer treatment and prevention, today announced that Dr.

）（'Atossa'或'公司'），一家致力于开发乳腺癌治疗和预防新方法的临床阶段生物制药公司，今天宣布Dr.

Steven Quay

史蒂文·奎

, Chairman and Chief Executive Officer, will participate in a fireside chat with biotech research analyst,

董事长兼首席执行官，将与生物技术研究分析师进行炉边谈话，

Emily Bodnar

艾米丽·博德纳尔

, at the H.C. Wainwright (HCW) 27th Annual Global Investment Conference on

在H.C. Wainwright（HCW）第27届年度全球投资会议上

Monday, September 8, 2025

2025年9月8日，星期一

, at

，在

3:00 p.m. ET

下午3点（东部时间）

, at the Lotte New York Palace Hotel in

，位于纽约洛特宫酒店

New York City

纽约市

。

继续阅读

Atossa Therapeutics CEO to Discuss Clinical Progress and Upcoming Milestones at 27th Annual H.C. Wainwright Global Investment Conference

Atossa Therapeutics首席执行官将在第27届H.C. Wainwright全球投资大会上讨论临床进展和即将到来的里程碑。

Dr. Quay will provide an update on Atossa's lead program, (Z)-endoxifen, a highly potent Selective Estrogen Receptor Modulator (SERM) with dual mechanisms of action that may offer a differentiated solution for women in both prevention and treatment settings of breast cancer. This includes progress across multiple clinical studies and encouraging feedback recently received by regulatory advisors that could accelerate the Company's path forward..

奎博士将提供阿托萨公司主要项目（Z）-恩多昔芬的最新进展，这是一种高效的选择性雌激素受体调节剂（SERM），具有双重作用机制，可能为女性在乳腺癌预防和治疗方面提供差异化解决方案。这包括多个临床研究的进展以及监管顾问最近收到的令人鼓舞的反馈，这些反馈可能会加速公司的发展进程。

The live presentation will be webcast, with a replay available for approximately 90 days on the Company's investor website:

现场演示将进行网络直播，并且在公司投资者网站上大约90天内可以观看回放：

https://investors.atossatherapeutics.com

In addition, a 60-second video message from Dr. Quay previewing the presentation is now available here, offering a personal invitation to learn more of Atossa's vision and upcoming catalysts.

此外，Quay博士的一段60秒视频预告已在此处发布，诚挚邀请您了解更多关于Atossa的愿景及即将来临的催化剂。

Investors interested in scheduling meetings with Atossa management may do so through the HCW conference portal, via their HCW representative, or directly by contacting a Company representative.

有兴趣安排与Atossa管理层会面的投资者可以通过HCW会议门户网站、其HCW代表或直接联系公司代表进行安排。

About Atossa Therapeutics

关于Atossa Therapeutics

Atossa Therapeutics, Inc. (Nasdaq:

阿托萨治疗公司 (纳斯达克:

ATOS

阿托斯

) is a clinical-stage biopharmaceutical company dedicated to transforming breast cancer treatment and prevention through innovative science and patient-focused solutions. The Company's lead product candidate, (Z)-endoxifen, is being developed as a therapy across the breast cancer spectrum, including prevention and treatment settings.

）是一家处于临床阶段的生物制药公司，致力于通过创新科学和以患者为中心的解决方案来变革乳腺癌的治疗和预防。该公司的主要候选产品（Z）-恩多昔芬正在被开发用于乳腺癌全谱的治疗，包括预防和治疗领域。

For more information, please visit .

如需更多信息，请访问。

www.atossatherapeutics.com

。

Forward-Looking Statements

前瞻性声明

This press release contains certain information that may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We may identify these forward-looking statements by the use of words such as 'expect,' 'potential,' 'continue,' 'may,' 'will,' 'should,' 'could,' 'would,' 'seek,' 'intend,' 'plan,' 'estimate,' 'anticipate,' 'believe,' 'design,' 'predict,' 'future,' or other comparable words.

本新闻稿包含某些可能构成1995年《私人证券诉讼改革法案》含义内的前瞻性陈述的信息。我们可能会通过使用诸如“预期”、“潜力”、“继续”、“可能”、“将”、“应该”、“可以”、“会”、“寻求”、“意图”、“计划”、“估计”、“预期”、“相信”、“设计”、“预测”、“未来”或其他类似词语来标识这些前瞻性陈述。

All statements made in this press release that are not statements of historical fact, including statements regarding the Company's development strategy and related milestones, data related to the (Z)-endoxifen program, the safety, tolerability and efficacy of (Z)-endoxifen, the potential of (Z)-endoxifen as a breast cancer prevention and treatment agent, the potential indications that the Company may pursue for (Z)-endoxifen, the potential for (Z)-endoxifen to receive regulatory approval, including the potential IND submission, Phase 3 trial and related timing, the expected timing of releasing data; benefits of the Company's strategy of pursuing a metastatic indication for (Z)-endoxifen, the expected design and enrollment of trials and timing of data and related publications, the Company's progress across its pipeline, the strength of the Company's patent portfolio and expectations regarding related litigation, and the potential market and growth opportunities for the Company, are forward-looking statements.

本新闻稿中所有非历史事实的陈述，包括关于公司发展战略及相关的里程碑、与(Z)-endoxifen项目相关的数据、(Z)-endoxifen的安全性、耐受性和有效性、(Z)-endoxifen作为乳腺癌预防和治疗剂的潜力、公司可能针对(Z)-endoxifen追求的潜在适应症、(Z)-endoxifen获得监管批准的潜力（包括潜在的IND提交、三期试验及相关时间）、数据发布的预期时间；公司追求(Z)-endoxifen转移性适应症策略的好处、试验的预期设计与招募以及数据和相关出版物的时间、公司在其产品线中的进展、公司专利组合的实力及对相关诉讼的预期、以及公司的潜在市场和增长机会，均为前瞻性陈述。

Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results, outcomes, or the timing of actual results or outcomes, to differ materially from those projected or anticipated, including risks and uncertainties associated with: our ability to obtain patent coverage for our .

本新闻稿中的前瞻性陈述受风险和不确定性的影响，可能导致实际结果、成果或实际结果或成果的时间与预期或预计的情况存在重大差异，包括与以下因素相关的风险和不确定性：我们获取专利覆盖的能力。

SOURCE Atossa Therapeutics Inc

来源：Atossa Therapeutics公司

WANT YOUR COMPANY'S NEWS

想要贵公司的新闻吗？

FEATURED ON PRNEWSWIRE.COM?

刊登在PRNEWSWIRE.COM上？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers